|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lagergren J, Smyth E, Cunningham D and
Lagergren P: Oesophageal cancer. Lancet. 390:2383–2396. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rustgi AK and El-Serag HB: Esophageal
carcinoma. N Engl J Med. 371:2499–2509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arnold M, Soerjomataram I, Ferlay J and
Forman D: Global incidence of oesophageal cancer by histological
subtype in 2012. Gut. 64:381–387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tanaka T, Fujita H, Matono S, Nagano T,
Nishimura K, Murata K, Shirouzu K, Suzuki G, Hayabuchi N and Yamana
H: Outcomes of multimodality therapy for stage IVB esophageal
cancer with distant organ metastasis (M1-Org). Dis Esophagus.
23:646–651. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu SG, Xie WH, Zhang ZQ, Sun JY, Li FY,
Lin HX, Yong Bao and He ZY: Surgery combined with radiotherapy
improved survival in metastatic esophageal cancer in a surveillance
epidemiology and end results population-based study. Sci Rep.
6:282802016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ai D, Zhu H, Ren W, Chen Y, Liu Q, Deng J,
Ye J, Fan J and Zhao K: Patterns of distant organ metastases in
esophageal cancer: A population-based study. J Thorac Dis.
9:3023–3030. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu SG, Zhang WW, He ZY, Sun JY, Chen YX
and Guo L: Sites of metastasis and overall survival in esophageal
cancer: A population-based study. Cancer Manag Res. 9:781–788.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu SG, Zhang WW, Sun JY, Li FY, Lin Q and
He ZY: Patterns of distant metastasis between histological types in
esophageal cancer. Front Oncol. 8:3022018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nielsen OS, Munro AJ and Tannock IF: Bone
metastases: Pathophysiology and management policy. J Clin Oncol.
9:509–524. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mundy GR: Metastasis to bone: Causes,
consequences and therapeutic opportunities. Nat Rev Cancer.
2:584–593. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coleman RE: Clinical features of
metastatic bone disease and risk of skeletal morbidity. Clin Cancer
Res. 12:6243s–6249s. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berenson JR, Rosen LS, Howell A, Porter L,
Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A and Seaman JJ:
Zoledronic acid reduces skeletal-related events in patients with
osteolytic metastases. Cancer. 91:1191–1200. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goodner JT and Turnbull AD: Bone
metastases in cancer of the esophagus. Am J Roentgenol Radium Ther
Nucl Med. 111:365–367. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma Z, Wu X, Xu B, Jiang H, Tang P, Yue J,
Ma M, Chen C, Zhang H and Yu Z: Development of a novel biomarker
model for predicting preoperative lymph node metastatic extent in
esophageal squamous cell carcinoma1. Oncotarget.
8:105790–105799. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang Y, Huang X, Zhou L, Deng T, Ning T,
Liu R, Zhang L, Bai M, Zhang H, Li H and Ba Y: Clinical use of
tumor biomarkers in prediction for prognosis and chemotherapeutic
effect in esophageal squamous cell carcinoma. BMC Cancer.
19:5262019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rybak LD and Rosenthal DI: Radiological
imaging for the diagnosis of bone metastases. Q J Nucl Med.
45:53–64. 2001.PubMed/NCBI
|
|
19
|
Kato H, Miyazaki T, Nakajima M, Takita J,
Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Fukuchi M, et al:
Comparison between whole-body positron emission tomography and bone
scintigraphy in evaluating bony metastases of esophageal
carcinomas. Anticancer Res. 25:4439–4444. 2005.PubMed/NCBI
|
|
20
|
Wu SG, Li H, Tang LY, Sun JY, Zhang WW, Li
FY, Chen YX and He ZY: The effect of distant metastases sites on
survival in de novo stage-IV breast cancer: A SEER database
analysis. Tumour Biol. 39:10104283177050822017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu M, Wang C, Gao L, Lv C and Cai X: A
nomogram to predict long-time survival for patients with M1
diseases of esophageal cancer. J Cancer. 9:3986–3990. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Katagiri H, Okada R, Takagi T, Takahashi
M, Murata H, Harada H, Nishimura T, Asakura H and Ogawa H: New
prognostic factors and scoring system for patients with skeletal
metastasis. Cancer Med. 3:1359–1367. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wedin R and Bauer HC: Surgical treatment
of skeletal metastatic lesions of the proximal femur:
Endoprosthesis or reconstruction nail? J Bone Joint Surg Br.
87:1653–1657. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Forsberg JA, Wedin R and Bauer H: Which
implant is best after failed treatment for pathologic femur
fractures? Clin Orthop Relat Res. 471:735–740. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Steensma M, Boland PJ, Morris CD,
Athanasian E and Healey JH: Endoprosthetic treatment is more
durable for pathologic proximal femur fractures. Clin Orthop Relat
Res. 470:920–926. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Araki N, Chuman H, Matsunobu T, Tanaka K,
Katagiri H, Kunisada T, Hiruma T, Hiraga H, Morioka H, Hatano H, et
al: Factors associated with the decision of operative procedure for
proximal femoral bone metastasis: Questionnaire survey to
institutions participating the Bone and Soft Tissue Tumor Study
Group of the Japan Clinical Oncology Group. J Orthop Sci.
22:938–945. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shimada H, Takeda A, Arima M, Okazumi S,
Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, et
al: Serum p53 antibody is a useful tumor marker in superficial
esophageal squamous cell carcinoma. Cancer. 89:1677–1683. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Munck-Wikland E, Kuylenstierna R, Wahren
B, Lindholm J and Haglund S: Tumor markers carcinoembryonic
antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the
esophagus. Pretreatment screening. Cancer. 62:2281–2286. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cao X, Zhang L, Feng GR, Yang J, Wang RY,
Li J, Zheng XM and Han YJ: Preoperative Cyfra21-1 and SCC-Ag serum
titers predict survival in patients with stage II esophageal
squamous cell carcinoma. J Transl Med. 10:1972012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shimada H, Nabeya Y, Okazumi S, Matsubara
H, Shiratori T, Gunji Y, Kobayashi S, Hayashi H and Ochiai T:
Prediction of survival with squamous cell carcinoma antigen in
patients with resectable esophageal squamous cell carcinoma.
Surgery. 133:486–494. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kosugi S, Nishimaki T, Kanda T, Nakagawa
S, Ohashi M and Hatakeyama K: Clinical significance of serum
carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous
cell carcinoma antigen levels in esophageal cancer patients. World
J Surg. 28:680–685. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang HQ, Wang RB, Yan HJ, Zhao W, Zhu KL,
Jiang SM, Hu XG and Yu JM: Prognostic significance of CYFRA21-1,
CEA and hemoglobin in patients with esophageal squamous cancer
undergoing concurrent chemoradiotherapy. Asian Pac J Cancer Prev.
13:199–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yi Y, Li B, Wang Z, Sun H, Gong H and
Zhang Z: CYFRA21-1 and CEA are useful markers for predicting the
sensitivity to chemoradiotherapy of esophageal squamous cell
carcinoma. Biomarkers. 14:480–485. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wagner AD, Unverzagt S, Grothe W, Kleber
G, Grothey A, Haerting J and Fleig WE: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev. CD0040642010.PubMed/NCBI
|
|
35
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi
E, et al: Phase III study of docetaxel and cisplatin plus
fluorouracil compared with cisplatin and fluorouracil as first-line
therapy for advanced gastric cancer: A report of the V325 Study
Group. J Clin Oncol. 24:4991–4997. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Al-Batran SE, Hartmann JT, Probst S,
Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G,
Homann N, Wilhelm G, et al: Phase III trial in metastatic
gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus
either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft
Internistische Onkologie. J Clin Oncol. 26:1435–1442. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ford HE, Marshall A, Bridgewater JA,
Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S,
Middleton GW, et al: Docetaxel versus active symptom control for
refractory oesophagogastric adenocarcinoma (COUGAR-02): An
open-label, phase 3 randomised controlled trial. Lancet Oncol.
15:78–86. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kang JH, Lee SI, Lim DH, Park KW, Oh SY,
Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, et al: Salvage
chemotherapy for pretreated gastric cancer: A randomized phase III
trial comparing chemotherapy plus best supportive care with best
supportive care alone. J Clin Oncol. 30:1513–1518. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hironaka S, Ueda S, Yasui H, Nishina T,
Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki
T, et al: Randomized, open-label, phase III study comparing
irinotecan with paclitaxel in patients with advanced gastric cancer
without severe peritoneal metastasis after failure of prior
combination chemotherapy using fluoropyrimidine plus platinum: WJOG
4007 trial. J Clin Oncol. 31:4438–4444. 2013. View Article : Google Scholar : PubMed/NCBI
|
